Wall Street brokerages predict that AxoGen, Inc. (NASDAQ:AXGN) will report $28.65 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AxoGen’s earnings. The highest sales estimate is $29.30 million and the lowest is $28.00 million. AxoGen posted sales of $24.26 million during the same quarter last year, which suggests a positive year-over-year growth rate of 18.1%. The firm is scheduled to issue its next earnings report after the market closes on Wednesday, May 5th.
According to Zacks, analysts expect that AxoGen will report full-year sales of $125.55 million for the current year, with estimates ranging from $124.00 million to $127.10 million. For the next year, analysts expect that the company will post sales of $144.90 million, with estimates ranging from $141.50 million to $148.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover AxoGen.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Sunday, February 21st. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.08. The business had revenue of $32.50 million for the quarter, compared to analysts’ expectations of $32.40 million. AxoGen had a negative return on equity of 19.83% and a negative net margin of 22.98%.
AxoGen stock traded up $1.01 during mid-day trading on Wednesday, hitting $19.29. The stock had a trading volume of 218,951 shares, compared to its average volume of 242,541. The stock has a 50-day simple moving average of $20.01 and a two-hundred day simple moving average of $17.48. The stock has a market capitalization of $786.49 million, a PE ratio of -30.62 and a beta of 0.71. AxoGen has a 12 month low of $7.42 and a 12 month high of $22.89. The company has a current ratio of 7.45, a quick ratio of 6.81 and a debt-to-equity ratio of 0.42.
Institutional investors and hedge funds have recently modified their holdings of the business. Advisory Research Inc. bought a new position in AxoGen during the fourth quarter worth about $466,000. Skandinaviska Enskilda Banken AB publ raised its position in shares of AxoGen by 27.5% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 90,137 shares of the medical equipment provider’s stock worth $1,613,000 after purchasing an additional 19,431 shares during the period. Exchange Traded Concepts LLC raised its position in shares of AxoGen by 83.4% during the fourth quarter. Exchange Traded Concepts LLC now owns 104,869 shares of the medical equipment provider’s stock worth $1,877,000 after purchasing an additional 47,683 shares during the period. William Blair Investment Management LLC raised its position in shares of AxoGen by 6.5% during the fourth quarter. William Blair Investment Management LLC now owns 1,351,771 shares of the medical equipment provider’s stock worth $24,197,000 after purchasing an additional 82,686 shares during the period. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of AxoGen during the fourth quarter worth about $50,000. Hedge funds and other institutional investors own 78.38% of the company’s stock.
AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Article: Why is insider trading harmful?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.